Draffin J, Sanchez-Castillo C, Fernandez-Rodrigo A, Sanchez-Saez X, Avila J, Wagner F
EMBO J. 2020; 40(2):e105513.
PMID: 33197065
PMC: 7809792.
DOI: 10.15252/embj.2020105513.
Shin J, Son J, Kim W, Gwak J, Ju B
PLoS One. 2019; 14(7):e0219800.
PMID: 31361752
PMC: 6667200.
DOI: 10.1371/journal.pone.0219800.
Kakade V, Tao S, Rajagopal M, Zhou X, Li X, Yu A
J Mol Cell Biol. 2016; 8(6):464-476.
PMID: 27190311
PMC: 5181316.
DOI: 10.1093/jmcb/mjw022.
Guo G, Zhong C, Liu Y, Mao X, Zhang Z, Jin J
Dis Markers. 2015; 2015:289750.
PMID: 25922553
PMC: 4398933.
DOI: 10.1155/2015/289750.
Beurel E, Grieco S, Jope R
Pharmacol Ther. 2014; 148:114-31.
PMID: 25435019
PMC: 4340754.
DOI: 10.1016/j.pharmthera.2014.11.016.
GSK-3 as potential target for therapeutic intervention in cancer.
McCubrey J, Steelman L, Bertrand F, Davis N, Sokolosky M, Abrams S
Oncotarget. 2014; 5(10):2881-911.
PMID: 24931005
PMC: 4102778.
DOI: 10.18632/oncotarget.2037.
Multifaceted roles of GSK-3 and Wnt/β-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention.
McCubrey J, Steelman L, Bertrand F, Davis N, Abrams S, Montalto G
Leukemia. 2013; 28(1):15-33.
PMID: 23778311
PMC: 3887408.
DOI: 10.1038/leu.2013.184.
Knockdown of FRAT1 expression by RNA interference inhibits human glioblastoma cell growth, migration and invasion.
Guo G, Kuai D, Cai S, Xue N, Liu Y, Hao J
PLoS One. 2013; 8(4):e61206.
PMID: 23613813
PMC: 3629175.
DOI: 10.1371/journal.pone.0061206.
Identification and characterization of Wnt signaling pathway in keloid pathogenesis.
Igota S, Tosa M, Murakami M, Egawa S, Shimizu H, Hyakusoku H
Int J Med Sci. 2013; 10(4):344-54.
PMID: 23471552
PMC: 3590592.
DOI: 10.7150/ijms.5349.
Frizzled and LRP5/6 receptors for Wnt/β-catenin signaling.
MacDonald B, He X
Cold Spring Harb Perspect Biol. 2012; 4(12).
PMID: 23209147
PMC: 3504444.
DOI: 10.1101/cshperspect.a007880.
Modulation of GSK-3 as a Therapeutic Strategy on Tau Pathologies.
Medina M, Garrido J, Wandosell F
Front Mol Neurosci. 2011; 4:24.
PMID: 22007157
PMC: 3186940.
DOI: 10.3389/fnmol.2011.00024.
Lithium regulates keratinocyte proliferation via glycogen synthase kinase 3 and NFAT2 (nuclear factor of activated T cells 2).
Hampton P, Jans R, Flockhart R, Parker G, Reynolds N
J Cell Physiol. 2011; 227(4):1529-37.
PMID: 21678407
PMC: 4150531.
DOI: 10.1002/jcp.22872.
Deconstructing GSK-3: The Fine Regulation of Its Activity.
Medina M, Wandosell F
Int J Alzheimers Dis. 2011; 2011:479249.
PMID: 21629747
PMC: 3100567.
DOI: 10.4061/2011/479249.
Involvement of the residues of GSKIP, AxinGID, and FRATtide in their binding with GSK3beta to unravel a novel C-terminal scaffold-binding region.
Howng S, Hwang C, Hsu C, Hsu M, Teng C, Chou C
Mol Cell Biochem. 2010; 339(1-2):23-33.
PMID: 20043192
DOI: 10.1007/s11010-009-0366-0.
FRAT1 expression and its correlation with pathologic grade, proliferation, and apoptosis in human astrocytomas.
Guo G, Liu B, Zhong C, Zhang X, Mao X, Wang P
Med Oncol. 2009; 28(1):1-6.
PMID: 20041315
DOI: 10.1007/s12032-009-9402-x.
Glycogen synthase kinase 3: more than a namesake.
Rayasam G, Tulasi V, Sodhi R, Davis J, Ray A
Br J Pharmacol. 2009; 156(6):885-98.
PMID: 19366350
PMC: 2697722.
DOI: 10.1111/j.1476-5381.2008.00085.x.
GSK3 beta N-terminus binding to p53 promotes its acetylation.
Eom T, Jope R
Mol Cancer. 2009; 8:14.
PMID: 19265551
PMC: 2660897.
DOI: 10.1186/1476-4598-8-14.
Analysis of dishevelled localization and function in the early sea urchin embryo.
Leonard J, Ettensohn C
Dev Biol. 2007; 306(1):50-65.
PMID: 17433285
PMC: 2697034.
DOI: 10.1016/j.ydbio.2007.02.041.
Tissue microarray analysis of human FRAT1 expression and its correlation with the subcellular localisation of beta-catenin in ovarian tumours.
Wang Y, Hewitt S, Liu S, Zhou X, Zhu H, Zhou C
Br J Cancer. 2006; 94(5):686-91.
PMID: 16479254
PMC: 2361213.
DOI: 10.1038/sj.bjc.6602988.
Regulation of the interaction between glycogen synthase kinase 3 and the Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen.
Fujimuro M, Liu J, Zhu J, Yokosawa H, Hayward S
J Virol. 2005; 79(16):10429-41.
PMID: 16051835
PMC: 1182668.
DOI: 10.1128/JVI.79.16.10429-10441.2005.